Chromodomain-helicase-DNA-binding protein 4: a novel therapeutic target in liver cancer stem cells

2017 ◽  
Vol 6 (1) ◽  
pp. 12-12 ◽  
Author(s):  
Kouki Nio ◽  
Taro Yamashita ◽  
Shuichi Kaneko
Keyword(s):  
Stem Cells ◽  
Dna Binding ◽  
Cancer Stem Cells ◽  
Liver Cancer ◽  
Therapeutic Target ◽  
Binding Protein ◽  
Dna Binding Protein ◽  
Liver Cancer Stem Cells ◽  
Novel Therapeutic

scholarly journals CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment

Oncotarget ◽  
2016 ◽  
Vol 7 (15) ◽  
pp. 20395-20409 ◽  
Author(s):  
Ji-Young Kim ◽  
Hwa-Yong Lee ◽  
Kwan-Kyu Park ◽  
Yang-Kyu Choi ◽  
Jeong-Seok Nam ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Liver Cancer ◽  
Cancer Treatment ◽  
Therapeutic Approach ◽  
Liver Cancer Stem Cells ◽  
Novel Therapeutic

scholarly journals Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Apolonia Novillo ◽  
Ana Fernández-Santander ◽  
Maria Gaibar ◽  
Miguel Galán ◽  
Alicia Romero-Lorca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Binding ◽  
Therapeutic Target ◽  
Binding Protein ◽  
Dna Binding Protein ◽  
Driver Mutations ◽  
Missense Mutations ◽  
Therapeutic Success ◽  
Nucleosome Remodeling ◽  
Novel Therapeutic

Chromodomain-helicase-DNA-binding protein 4 (CHD4) is an epigenetic regulator identified as an oncogenic element that may provide a novel therapeutic target for the treatment of breast cancer (BC). CHD4—the core component of the nucleosome remodeling and deacetylase (NuRD) complex—may be mutated in patients with this disease. However, information on CHD4 mutants that might allow their use as biomarkers of therapeutic success and prognosis is lacking. The present work examines mutations in CHD4 reported in patients with breast cancer and included in public databases and attempts to identify their roles in its development. The databases revealed 81 point mutations across different types of breast cancer (19 of which also appeared in endometrial, intestinal, nervous system, kidney, and lymphoid organ cancers). 71.6% of the detected mutations were missense mutations, 13.6% were silent, and 6.2% nonsense. Over 50% affected conserved residues of the ATPase motor (ATPase and helicase domains), and domains of unknown function in the C-terminal region. Thirty one mutations were classified in the databases as either ‘deleterious’, ‘probably/possibly damaging’ or as ‘high/medium pathogenic’; another five nonsense and one splice-site variant were predicted to produce potentially harmful truncated proteins. Eight of the 81 mutations were categorized as putative driver mutations and have been found in other cancer types. Some mutations seem to influence ATPase and DNA translocation activities (R1162W), while others may alter protein stability (R877Q/H, R975H) or disrupt DNA binding and protein activity (R572*, X34_splice) suggesting CHD4 function may be affected. In vivo tumorigenecity studies in endometrial cancer have revealed R975H and R1162W as mutations that lead to CHD4 loss-of-function. Our study provides insight into the molecular mechanism whereby CHD4, and some of its mutants could play a role in breast cancer and suggest important implications for the biological comprehension and prognosis of breast cancer, identifying CHD4 as a novel therapeutic target for BC patients.

scholarly journals CD13 is a therapeutic target in human liver cancer stem cells

2010 ◽  
Vol 120 (9) ◽  
pp. 3326-3339 ◽  
Author(s):  
Naotsugu Haraguchi ◽  
Hideshi Ishii ◽  
Koshi Mimori ◽  
Fumiaki Tanaka ◽  
Masahisa Ohkuma ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Liver Cancer ◽  
Therapeutic Target ◽  
Human Liver ◽  
Liver Cancer Stem Cells ◽  
Human Liver Cancer

scholarly journals Liver cancer stem cells: implications for a new therapeutic target

2009 ◽  
Vol 29 (7) ◽  
pp. 955-965 ◽  
Author(s):  
Terence Kin Wah Lee ◽  
Antonia Castilho ◽  
Stephanie Ma ◽  
Irene Oi Lin Ng
Keyword(s):  
Stem Cells ◽  
Cancer Stem Cells ◽  
Liver Cancer ◽  
Therapeutic Target ◽  
Liver Cancer Stem Cells
Sign in / Sign up

Export Citation Format

Share Document